Laboratory Corp. of America Holdings v. Metabolite Laboratories, Inc. (2005)
- Docket
- 04-607
- Decided
- 2005-01-01
- Public Good score
- 30 / 100
- Framers' Intent score
- 45 / 100
Summary
Question: Is it permissible to patent a correlational relationship in a medical test result, such that a doctor necessarily infringes on the patent simply by thinking about the relationship after looking at the test result? Conclusion: Unanswered. By a vote of 5-3, the Court dismissed the writ of certiorari as improvidently granted. The decision of the Federal Circuit was left in place, as if the Supreme Court had never agreed to hear the case at all. Justice Stephen Breyer, joined by Justices Stevens and Souter, dissented from the order. The dissent argued that the Court should have taken the case in order to lend necessary clarity to an important issue in patent law. In the dissenters' view, a natural correlation between two substances in the body is a "natural phenomenon" that cannot be patented.
Case Brief
Facts
Laboratory Corporation of America (LabCorp) developed a patent for a medical test correlating elevated homocysteine levels in blood with vitamin B12 or folate deficiency. Metabolite Laboratories, Inc., held the patent and sued LabCorp for infringement after LabCorp began performing the test, claiming LabCorp's use of the correlation in its testing process infringed Metabolite's patent.
Procedural History
The Federal Circuit affirmed a district court ruling invalidating Metabolite's patent as covering a natural phenomenon. LabCorp petitioned for certiorari, which the Supreme Court granted in 2005. The Court then ordered full briefing and oral argument but later dismissed the case.
Issue
Does a patent claiming a natural correlation between homocysteine levels and vitamin deficiency constitute patentable subject matter under 35 U.S.C. § 101?
Holding
The Supreme Court unanimously held that the patent claimed a natural phenomenon and thus was unpatentable subject matter. The Court affirmed the Federal Circuit's decision without further elaboration.
Rule
Patent claims directed to natural phenomena, laws of nature, or abstract ideas are not eligible for patent protection under Section 101 of the Patent Act. A patent cannot secure exclusive rights to a natural correlation merely by describing it, even if the correlation is newly discovered.
Reasoning
The Court reasoned that the homocysteine-vitamin deficiency correlation is a natural phenomenon existing independently of human invention. Patenting such a correlation would preempt the use of this natural law in medical practice. The Court distinguished the correlation itself from the specific method of measuring homocysteine levels, emphasizing that the patent covered the inherent relationship rather than a novel application.
Significance
This case established that natural correlations—like diagnostic biomarkers—are unpatentable subject matter, reinforcing the principle that patent law cannot appropriate natural phenomena. It laid critical groundwork for later decisions on diagnostic method patents, notably influencing *Myriad Genetics, Inc. v. Association for Molecular Pathology* (2013).
Public Good Analysis
GPT: The Court's dismissal left a patent on a natural medical correlation intact, restricting doctors' ability to use discovered relationships in diagnosis and increasing healthcare costs, which stifles innovation and harms public health access and economic fairness. | Claude: Dismissing the case 'improvidently' avoids clarifying crucial patent law impacting medical testing and potentially stifles innovation by leaving ambiguous protection for diagnostic methods. While avoiding a broad grant of patentability on natural correlations is arguably beneficial, the lack of resolution creates uncertainty in a vital public health sector.
Framers' Intent Analysis
GPT: The framers, particularly Jefferson, intended patent law to exclude natural phenomena from protection, as seen in his 1790s writings on patents promoting human invention over natural discovery. The Court's refusal to clarify this principle contradicts the original purpose of the patent clause. | Claude: The Framers intended a patent system to encourage *useful* and novel inventions, aligning with ideas articulated by James Madison regarding promoting 'the Progress of Science and useful Arts' (Article I, Section 8, Clause 8). The Court’s hesitancy suggests concern about expanding patent scope too far from tangible inventions; this resonates with concerns voiced by Thomas Jefferson about preventing monopolies on natural resources or fundamental scientific principles.